• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

两例癌症患者接受活生物体抗癌疫苗治疗后发生播散性感染。

Two cases of disseminated infection following live organism anti-cancer vaccine administration in cancer patients.

机构信息

University of South Florida Morsani College of Medicine, 12901 Bruce B Downs Blvd, Tampa, FL 33612, United States.

H. Lee Moffitt Cancer Center, University of South Florida Morsani College of Medicine, 12902 Magnolia Drive, Tampa, FL 33612-9497, United States.

出版信息

Int J Infect Dis. 2018 Jul;72:1-2. doi: 10.1016/j.ijid.2018.04.004. Epub 2018 Apr 12.

DOI:10.1016/j.ijid.2018.04.004
PMID:29656135
Abstract

Vaccines containing live attenuated bacterial or viral organisms are currently being investigated as potential therapy for locally advanced or metastatic cancers. However, the use of such live organisms in an immunocompromised population, such as patients who recently or are currently receiving chemotherapy, raises the concern that these organisms can themselves disseminate and cause frank infection. We report a hereunto unreported phenomenon of anti-cancer vaccines (containing live attenuated organisms) leading to frank, disseminated infection. We submit that occurrence of this phenomenon must be watched for by all members of the interdisciplinary cancer treatment team.

摘要

目前,含有减毒活细菌或病毒的疫苗正被作为局部晚期或转移性癌症的潜在治疗方法进行研究。然而,在免疫功能低下的人群(如最近或正在接受化疗的患者)中使用此类活生物体引起了人们的担忧,即这些生物体本身可能会传播并导致明显感染。我们报告了一种迄今为止尚未报道的现象,即抗癌疫苗(含减毒活生物体)导致明显的、播散性感染。我们认为,这种现象的发生必须引起肿瘤多学科治疗团队所有成员的关注。

相似文献

1
Two cases of disseminated infection following live organism anti-cancer vaccine administration in cancer patients.两例癌症患者接受活生物体抗癌疫苗治疗后发生播散性感染。
Int J Infect Dis. 2018 Jul;72:1-2. doi: 10.1016/j.ijid.2018.04.004. Epub 2018 Apr 12.
2
A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.用于晚期癌症的减毒李斯特菌疫苗(ANZ-100)和表达间皮素的减毒李斯特菌疫苗(CRS-207):安全性和免疫原性的 I 期研究。
Clin Cancer Res. 2012 Feb 1;18(3):858-68. doi: 10.1158/1078-0432.CCR-11-2121. Epub 2011 Dec 6.
3
Letter from the Editor.编辑来信。
Hum Vaccin Immunother. 2015;11(10):2333. doi: 10.1080/21645515.2015.1083786.
4
Systemic listeriosis following vaccination with the attenuated Listeria monocytogenes therapeutic vaccine, ADXS11-001.接种减毒单核细胞增生李斯特菌治疗性疫苗ADXS11 - 001后发生的全身性李斯特菌病。
Hum Vaccin Immunother. 2016 Apr 2;12(4):1085-6. doi: 10.1080/21645515.2015.1121338. Epub 2015 Nov 30.
5
Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.基于单核细胞增生李斯特菌的免疫疗法发展的前景与挑战。
Expert Rev Vaccines. 2008 Sep;7(7):1069-84. doi: 10.1586/14760584.7.7.1069.
6
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.GVAX胰腺疫苗初免联合表达间皮素的单核细胞增生李斯特菌(CRS-207)加强疫苗用于转移性胰腺癌的安全性及生存情况
J Clin Oncol. 2015 Apr 20;33(12):1325-33. doi: 10.1200/JCO.2014.57.4244. Epub 2015 Jan 12.
7
Listeria as a vaccine vector.作为疫苗载体的李斯特菌。
Microbes Infect. 2007 Aug;9(10):1226-35. doi: 10.1016/j.micinf.2007.05.010. Epub 2007 May 7.
8
The defined attenuated Listeria monocytogenes delta mp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma.经鉴定的减毒单核细胞增生李斯特菌delta mp12突变体是一种有效的口服疫苗载体,可引发针对小鼠纤维肉瘤的持久免疫反应。
Eur J Immunol. 1997 Jun;27(6):1570-5. doi: 10.1002/eji.1830270637.
9
Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts.免疫功能低下患者及其密切接触者活病毒和活细菌疫苗的推荐意见。
J Allergy Clin Immunol. 2014 Apr;133(4):961-6. doi: 10.1016/j.jaci.2013.11.043. Epub 2014 Feb 28.
10
Recent advances in the development of live, attenuated bacterial vectors.减毒活细菌载体开发的最新进展。
Curr Opin Mol Ther. 2005 Feb;7(1):62-72.

引用本文的文献

1
Harnessing live vectors for cancer vaccines: Advancing therapeutic immunotherapy.利用活载体研发癌症疫苗:推进治疗性免疫疗法。
Hum Vaccin Immunother. 2025 Dec;21(1):2469416. doi: 10.1080/21645515.2025.2469416. Epub 2025 Mar 24.
2
Safety of a Novel -Based Vaccine Vector Expressing NcSAG1 ( Surface Antigen 1).新型基于疫苗载体的 NcSAG1(表面抗原 1)表达的安全性。
Front Cell Infect Microbiol. 2021 Aug 25;11:675219. doi: 10.3389/fcimb.2021.675219. eCollection 2021.
3
Clinical Experience and Recent Advances in the Development of -Based Tumor Immunotherapies.
基于 的肿瘤免疫疗法的临床经验和最新进展。
Front Immunol. 2021 Apr 14;12:642316. doi: 10.3389/fimmu.2021.642316. eCollection 2021.
4
cancer vaccines: bridging innate and adaptive immunity.癌症疫苗:连接固有免疫和适应性免疫
Curr Clin Microbiol Rep. 2019 Dec;6(4):213-224. doi: 10.1007/s40588-019-00133-4. Epub 2019 Nov 20.
5
Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector.犬骨肉瘤活李斯特菌载体疫苗的安全性评价。
Vet Comp Oncol. 2021 Mar;19(1):92-98. doi: 10.1111/vco.12642. Epub 2020 Aug 17.
6
RIPK3 and Caspase-1/11 Are Necessary for Optimal Antigen-Specific CD8 T Cell Response Elicited by Genetically Modified .RIPK3 和 Caspase-1/11 对于由基因修饰的 …… 引发的最佳抗原特异性 CD8 T 细胞反应是必需的。
Front Immunol. 2020 Apr 9;11:536. doi: 10.3389/fimmu.2020.00536. eCollection 2020.
7
Vaccine strain Listeria monocytogenes abscess in a dog: a case report.犬感染疫苗株单核细胞增生李斯特菌脓肿:一例报告
BMC Vet Res. 2019 Dec 21;15(1):467. doi: 10.1186/s12917-019-2216-y.
8
Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug Delivery.利用脂质体与免疫系统的相互作用实现癌症药物递送的下一次突破。
Front Pharmacol. 2019 Mar 12;10:220. doi: 10.3389/fphar.2019.00220. eCollection 2019.
9
Vaccine strain Listeria monocytogenes bacteremia occurring 31 months after immunization.疫苗株李斯特菌菌血症发生在免疫后 31 个月。
Infection. 2019 Jun;47(3):489-492. doi: 10.1007/s15010-018-1249-7. Epub 2018 Nov 14.
10
as a Vector for Cancer Immunotherapy: Current Understanding and Progress.作为癌症免疫治疗的载体:当前的认识与进展
Vaccines (Basel). 2018 Jul 25;6(3):48. doi: 10.3390/vaccines6030048.